Are low-dose cannabis oils safe and effective for MS symptoms?
A prospective study of 28 MS patients found that low-dose medical cannabis oils (mean 4 mg THC, 7 mg CBD daily) were safe and well-tolerated, with significant reductions in pain, spasticity, and sleep disturbances over four weeks without impairing cognitive or physical function.
Quick Facts
What This Study Found
Pain decreased from median NRS 7 to 4 (p=0.01), spasticity from 6 to 2.5 (p=0.01), and sleep disturbances from 7 to 3 (p<0.001). Most common adverse events were mild dry mouth, drowsiness, dizziness, and nausea. Two patients discontinued due to excessive dreaming and drowsiness. No impairment in disability (EDSS), ambulation, dexterity, or processing speed.
Key Numbers
28 patients; mean THC dose 4 mg, CBD dose 7 mg; mostly once-daily evening; pain NRS 7 to 4 (p=0.01); spasticity 6 to 2.5 (p=0.01); sleep 7 to 3 (p<0.001); 2 discontinuations; 3 SAEs unrelated to treatment; no cognitive/physical impairment
How They Did This
Prospective observational safety study of 28 MS patients treated with medical cannabis oils (THC-rich, CBD-rich, and THC+CBD combined). Four-week titration period with assessments at baseline and 4 weeks including EDSS, T25FWT, 9-HPT, SDMT, blood tests, and plasma cannabinoid levels. Daily NRS ratings for symptoms.
Why This Research Matters
The low doses used (mean 4 mg THC) are much lower than typical recreational or even medical cannabis use. Demonstrating safety and efficacy at these doses could make medical cannabis more accessible to patients and clinicians who are concerned about side effects and impairment.
The Bigger Picture
The "start low, go slow" approach with cannabis oils is increasingly recommended but rarely studied prospectively. This study provides evidence that even very low doses can meaningfully reduce MS symptoms without the cognitive and motor side effects that concern patients and clinicians.
What This Study Doesn't Tell Us
Small sample (28 patients). No control group; improvements could reflect placebo effect. Short follow-up (4 weeks). Open-label design means patients knew they were receiving cannabis.
Questions This Raises
- ?Would a randomized, placebo-controlled trial confirm these findings?
- ?Are the benefits sustained beyond 4 weeks?
- ?Which cannabis oil formulation (THC-rich, CBD-rich, or combined) is most effective for which MS symptoms?
Trust & Context
- Key Stat:
- Pain: 7 to 4; Spasticity: 6 to 2.5
- Evidence Grade:
- Prospective safety study with validated outcome measures, but small sample, no control group, and short follow-up.
- Study Age:
- Published in 2021; low-dose cannabis oil research in MS is still in early stages.
- Original Title:
- Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis.
- Published In:
- Multiple sclerosis and related disorders, 48, 102708 (2021)
- Authors:
- S, Gustavsen, Hb, Søndergaard, K, Linnet, R, Thomsen, Bs, Rasmussen, Ps, Sorensen, F, Sellebjerg, Ab, Oturai
- Database ID:
- RTHC-03480
Evidence Hierarchy
Enrolls participants and follows them forward in time.
What do these levels mean? →Frequently Asked Questions
How much cannabis oil do you need for MS?
This study found meaningful symptom relief at very low doses: an average of just 4 mg THC and 7 mg CBD daily, usually taken as a single evening dose. This is much lower than typical recreational doses.
Does cannabis oil affect thinking or walking in MS?
At these low doses, no impairment was detected in disability scores, walking speed, hand dexterity, or processing speed over the 4-week study period.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03480APA
S, Gustavsen; Hb, Søndergaard; K, Linnet; R, Thomsen; Bs, Rasmussen; Ps, Sorensen; F, Sellebjerg; Ab, Oturai. (2021). Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis.. Multiple sclerosis and related disorders, 48, 102708. https://doi.org/10.1016/j.msard.2020.102708
MLA
S, Gustavsen, et al. "Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis.." Multiple sclerosis and related disorders, 2021. https://doi.org/10.1016/j.msard.2020.102708
RethinkTHC
RethinkTHC Research Database. "Safety and efficacy of low-dose medical cannabis oils in mul..." RTHC-03480. Retrieved from https://rethinkthc.com/research/s-2021-safety-and-efficacy-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.